Laura Buyan-Dent
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laura Buyan-Dent has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Jennifer L. Perrault
Wisconsin Institute for Translational Neuroengineering, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
2 shared publications- Jordan N. Ranum
Department of Neurological Surgery, University of Wisconsin School of Medicine and Public Health, Madison
2 shared publications Aaron J. Suminski
Department of Neurological Surgery, University of Wisconsin School of Medicine and Public Health, Madison
1 shared publication- Aaron J. Suminski
Department of Neurological Surgery, University of Wisconsin-Madison
1 shared publication - Aayush Goud
Wisconsin Institute for Translational Neuroengineering, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
1 shared publication Ananya Heroor
University of Wisconsin-Madison, College of Letters and Science, Madison, WI, USA
1 shared publication
Latest Publications
- 23 September 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 153, 108994
An examination of the effect of dual task on gait in Parkinson's disease and REM sleep behavior disorder
- 23 September 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 153, 108994
An examination of the effect of dual task on gait in Parkinson's disease and REM sleep behavior disorder
- Open Access
- 20 July 2026
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 12 (3)
Rescue deep brain stimulation for recurrent essential tremor after ventral intermediate nucleus thalamotomy: illustrative cases
BACKGROUND: Medication-refractory essential tremor (ET) patients who undergo MR-guided focused ultrasound or Gamma Knife thalamotomy may experience tremor recurrence, prompting rescue deep brain stimulation (DBS). Yet, the impact of prior ventral intermediate nucleus (VIM) lesioning on DBS targeting, microelectrode recording (MER), and stimulation programming remains uncertain. OBSERVATIONS: The authors present 3 ET patients undergoing bilateral DBS for tremor recurrence after thalamotomy. Thalamotomy lesions showed depressed electrophysiological activity versus nonlesioned VIM on MER (p = 0.0397) and required smaller DBS charge density increases for tremor control, suggesting irreversible lesion effects despite tremor recurrence. Tremor recurrence correlated with lesion mislocation; specifically, ablations missed the central VIM (mean 1.8 mm) and decussating dentato-rubro-thalamic tract. For rescue DBS, ventral VIM stimulation yields the greatest tremor reduction, while central VIM stimulation balanced tremor control with adverse effects. LESSONS: DBS is a safe, effective rescue treatment for failed thalamotomy without needing to retarget the prior lesion site. The authors advocate for prospective studies of initial DBS targeting 2 mm anterior to standard VIM coordinates, reducing intraoperative readjustment for central VIM stimulation; and initial thalamotomy targeting 1 mm anterior and 1.2–1.5 mm superior to standard coordinates for durable tremor control through ablation of both central and ventral VIM. https://thejns.org/doi/10.3171/CASE25955
- 20 July 2026
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 12 (3)
Open AccessRescue deep brain stimulation for recurrent essential tremor after ventral intermediate nucleus thalamotomy: illustrative cases
BACKGROUND: Medication-refractory essential tremor (ET) patients who undergo MR-guided focused ultrasound or Gamma Knife thalamotomy may experience tremor recurrence, prompting rescue deep brain stimulation (DBS). Yet, the impact of prior ventral intermediate nucleus (VIM) lesioning on DBS targeting, microelectrode recording (MER), and stimulation programming remains uncertain. OBSERVATIONS: The authors present 3 ET patients undergoing bilateral DBS for tremor recurrence after thalamotomy. Thalamotomy lesions showed depressed electrophysiological activity versus nonlesioned VIM on MER (p = 0.0397) and required smaller DBS charge density increases for tremor control, suggesting irreversible lesion effects despite tremor recurrence. Tremor recurrence correlated with lesion mislocation; specifically, ablations missed the central VIM (mean 1.8 mm) and decussating dentato-rubro-thalamic tract. For rescue DBS, ventral VIM stimulation yields the greatest tremor reduction, while central VIM stimulation balanced tremor control with adverse effects. LESSONS: DBS is a safe, effective rescue treatment for failed thalamotomy without needing to retarget the prior lesion site. The authors advocate for prospective studies of initial DBS targeting 2 mm anterior to standard VIM coordinates, reducing intraoperative readjustment for central VIM stimulation; and initial thalamotomy targeting 1 mm anterior and 1.2–1.5 mm superior to standard coordinates for durable tremor control through ablation of both central and ventral VIM. https://thejns.org/doi/10.3171/CASE25955
- Open Access
- 21 February 2026
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 23 (2) , 269
Diagnosis and Management of Parkinson Disease in Individuals with Pre-Existing Mood Disorders
Parkinson disease (PD) and mood disorders represent two substantial global health burdens that increasingly co-occur as both conditions rise in prevalence worldwide. Diagnosing Parkinson disease in patients with pre-existing mood disorders is clinically challenging due to overlapping symptoms, medication effects, and shared neurobiological mechanisms. Apathy, psychomotor slowing, and fatigue may mimic depressive symptoms, leading to delayed recognition of early parkinsonism. Development of an underlying neurodegenerative disorder could account for some treatment-resistant symptoms or treatment failures if not recognized. Therefore, the identification of PD will change the treatment and management plan significantly. Accurate diagnosis of PD requires a detailed neurologic examination focusing on bradykinesia, rigidity, and resting tremor, supported when appropriate by dopamine transporter imaging (DaT scan) or other emerging biomarkers. Understanding the temporal relationship between psychiatric and motor features helps differentiate prodromal PD from primary mood disorders. Management of patients with both mood disorders and PD integrates dopaminergic replacement therapy for motor symptoms with individualized treatment of psychiatric comorbidities. Levodopa remains the cornerstone for motor control, while dopamine agonists, MAO-B inhibitors, and COMT inhibitors can be added as needed. For depression and anxiety, SSRIs and SNRIs are first-line choices; quetiapine or clozapine are preferred when treatment for psychosis is necessary. Intentional, thoughtful polypharmacy is frequently required. Non-pharmacologic interventions—including cognitive behavioral therapy, structured exercise, and patient–caregiver education—enhance mood, function, and quality of life. Multidisciplinary collaboration between neurology, psychiatry, and allied health professionals is essential for optimal outcomes. This review offers guidance to healthcare providers as well as other interested parties involved in patients with mood disorders who may also be developing or have PD, especially to those who may have limited access to neurologic resources.
- 21 February 2026
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 23 (2) , 269
Open AccessDiagnosis and Management of Parkinson Disease in Individuals with Pre-Existing Mood Disorders
Parkinson disease (PD) and mood disorders represent two substantial global health burdens that increasingly co-occur as both conditions rise in prevalence worldwide. Diagnosing Parkinson disease in patients with pre-existing mood disorders is clinically challenging due to overlapping symptoms, medication effects, and shared neurobiological mechanisms. Apathy, psychomotor slowing, and fatigue may mimic depressive symptoms, leading to delayed recognition of early parkinsonism. Development of an underlying neurodegenerative disorder could account for some treatment-resistant symptoms or treatment failures if not recognized. Therefore, the identification of PD will change the treatment and management plan significantly. Accurate diagnosis of PD requires a detailed neurologic examination focusing on bradykinesia, rigidity, and resting tremor, supported when appropriate by dopamine transporter imaging (DaT scan) or other emerging biomarkers. Understanding the temporal relationship between psychiatric and motor features helps differentiate prodromal PD from primary mood disorders. Management of patients with both mood disorders and PD integrates dopaminergic replacement therapy for motor symptoms with individualized treatment of psychiatric comorbidities. Levodopa remains the cornerstone for motor control, while dopamine agonists, MAO-B inhibitors, and COMT inhibitors can be added as needed. For depression and anxiety, SSRIs and SNRIs are first-line choices; quetiapine or clozapine are preferred when treatment for psychosis is necessary. Intentional, thoughtful polypharmacy is frequently required. Non-pharmacologic interventions—including cognitive behavioral therapy, structured exercise, and patient–caregiver education—enhance mood, function, and quality of life. Multidisciplinary collaboration between neurology, psychiatry, and allied health professionals is essential for optimal outcomes. This review offers guidance to healthcare providers as well as other interested parties involved in patients with mood disorders who may also be developing or have PD, especially to those who may have limited access to neurologic resources.
- Open Access
- 6 June 2025
- Published by Elsevier in Brain Stimulation
- Vol. 18 (4) , 1162-1173
Wearable peripheral nerve stimulator reduces essential tremor symptoms through targeted brain modulation
- 6 June 2025
- Published by Elsevier in Brain Stimulation
- Vol. 18 (4) , 1162-1173
Open AccessWearable peripheral nerve stimulator reduces essential tremor symptoms through targeted brain modulation